They are not currently trying to carve anything out, since the only current indication is the Marine indication. The point is that if/when V is approved for the broader Reduce-It indication, the generics would not need to match that broader label in order to sell V for the Marine indication (assuming they prevail in the lawsuit).
News 
Market Data 
Discover 
